Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
ValiRx plc ( (GB:VAL) ) has issued an announcement.
ValiRx plc has successfully raised £1,573,000 through a fundraising initiative, which includes the subscription of 38,461,538 Broker Offer Shares, amounting to £250,000. This fundraising effort will support the company’s endeavors in advancing its pipeline of cancer therapeutics and women’s health products. The CEO, Mark Eccleston, has significantly increased his shareholding, demonstrating confidence in the company’s strategic direction. The newly issued shares are set to be admitted to AIM, following shareholder approval, further solidifying ValiRx’s position in the market and providing potential for growth and development.
More about ValiRx plc
ValiRx is a life science company that focuses on early-stage cancer therapeutics and women’s health. It aims to accelerate the translation of innovative science into impactful medicines to improve patient lives by providing a scientific, financial, and commercial framework for rapid clinical development. ValiRx selects and incubates promising drug candidates and guides them through an optimized development process, from pre-clinical studies to investor-ready assets, often partnering with investors for further clinical development and commercialization.
YTD Price Performance: -86.86%
Average Trading Volume: 1,183,396
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £1.03M
For detailed information about VAL stock, go to TipRanks’ Stock Analysis page.
